Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs that Destabilize Microtubules

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: 5-HT₃ Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Erratum: Molecular determinants of response to PI3K/AKT/mTOR and KRAS pathways inhibitors in NSCLC cell lines.

American journal of cancer research·2026

Same author

Editorial: Innovative drug combinations for enhanced solid tumor treatment efficacy.

Frontiers in oncology·2026

Same author

Early molecular changes predict cancer cachexia in LKB1-deleted mouse models of NSCLC.

Clinical and translational medicine·2025

Same author

The Landscape of PARP Inhibitors in Solid Cancers.

OncoTargets and therapy·2025

Same author

Small molecule-mediated inhibition of the oxidoreductase ERO1A restrains aggressive breast cancer by impairing VEGF and PD-L1 in the tumor microenvironment.

Cell death & disease·2025

Same author

Detection of aberrant locomotor activity in a mouse model of lung cancer via home cage monitoring.

Frontiers in oncology·2025

Search research articles

Related Experiment Video

Updated: May 12, 2026

Establishing 3-Dimensional Spheroids from Patient-Derived Tumor Samples and Evaluating their Sensitivity to Drugs

Establishing 3-Dimensional Spheroids from Patient-Derived Tumor Samples and Evaluating their Sensitivity to Drugs

Published on: December 16, 2022

Nemorubicin.

Massimo Broggini¹

¹Istituto di Ricerche Farmacologiche Mario Negri, Via La Masa 19, 20156, Milan, Italy, broggini@marionegri.it.

Topics in Current Chemistry

|April 23, 2013

Summary

Nemorubicin, a doxorubicin derivative, shows potent activity against multi-drug resistant tumors. Its unique mechanism, involving nucleotide excision repair, offers a promising alternative in cancer chemotherapy.

Area of Science:

Oncology
Medicinal Chemistry
Pharmacology

Background:

Doxorubicin is a widely used chemotherapy agent but faces challenges with drug resistance.
Chemoresistance, particularly multi-drug resistance (MDR), limits the efficacy of conventional treatments.
Development of novel anthracyclines is crucial to overcome resistance mechanisms.

Purpose of the Study:

To evaluate the efficacy of nemorubicin, a novel doxorubicin derivative, against resistant cancer models.
To understand the mechanism of action and metabolic profile of nemorubicin.
To assess the potential of nemorubicin as a therapeutic agent in clinical settings.

Main Methods:

Synthesis of nemorubicin as a 3'-deamino-3'[2-(S)-methoxy-4-morpholinyl] derivative of doxorubicin.

More Related Videos

A Three-dimensional Model of Spheroids to Study Colon Cancer Stem Cells

A Three-dimensional Model of Spheroids to Study Colon Cancer Stem Cells

Published on: January 22, 2021

Development and Standardization of an Ex Vivo Micromethod for Intracellular Quantification of Vincristine in Primary ALL Cells by LC-MS/MS

Development and Standardization of an Ex Vivo Micromethod for Intracellular Quantification of Vincristine in Primary ALL Cells by LC-MS/MS

Published on: January 23, 2026

Related Experiment Videos

Last Updated: May 12, 2026

Establishing 3-Dimensional Spheroids from Patient-Derived Tumor Samples and Evaluating their Sensitivity to Drugs

Establishing 3-Dimensional Spheroids from Patient-Derived Tumor Samples and Evaluating their Sensitivity to Drugs

Published on: December 16, 2022

A Three-dimensional Model of Spheroids to Study Colon Cancer Stem Cells

A Three-dimensional Model of Spheroids to Study Colon Cancer Stem Cells

Published on: January 22, 2021

Development and Standardization of an Ex Vivo Micromethod for Intracellular Quantification of Vincristine in Primary ALL Cells by LC-MS/MS

Development and Standardization of an Ex Vivo Micromethod for Intracellular Quantification of Vincristine in Primary ALL Cells by LC-MS/MS

Published on: January 23, 2026

In vitro testing against murine and human tumor cells resistant to doxorubicin.

In vivo studies in mice bearing multi-drug resistant tumors.

Investigation of metabolic activation via P450 CYP3A enzyme.

Main Results:

Nemorubicin demonstrated in vitro activity against doxorubicin-resistant cells.
In vivo studies confirmed nemorubicin's efficacy in mice with multi-drug resistant tumors.
The compound retained activity against alkylating agent and topoisomerase II resistant tumors.
Nemorubicin and its metabolite exhibit a distinct mechanism of action involving nucleotide excision repair.

Conclusions:

Nemorubicin is a potent doxorubicin analogue effective against various resistant cancer types.
Its unique mechanism of action and metabolic profile differentiate it from doxorubicin.
Nemorubicin shows promise for clinical application, alone or in combination therapy.